Research confirms that there is a new cure for multidrug-resistant tuberculosis

Zhang Tianyu, State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences & Guangdong-Hong Kong-Macao Respiratory System Infectious Diseases Joint Experimental Researcher Zhang Tianyu's research team and Zhong Nanshan, Academician of the Chinese Academy of Engineering, University of Auckland & University of Otago Professor Cook Gregory and Russia Professor Maslov Dmitry of the Academy of Sciences has confirmed that the new drug TB47 and the patent expired old drug form a pure oral combination, which is expected to cure multidrug-resistant tuberculosis within 4 months
.
Related research was published online in "Antimicrobial Agents and Chemotherapy" on September 17

Tuberculosis, commonly known as tuberculosis, is a fatal disease caused by Mycobacterium tuberculosis (TB bacterium for short), and pulmonary tuberculosis is the most common
.
With the continuous emergence of drug-resistant tuberculosis, tuberculosis is in danger of resurgence

The new anti-tuberculosis drug TB47 that targets the cytochrome bc1 oxidase complex of the respiratory chain of mycobacteria developed by Zhang Tianyu’s research group and clofazimine has a unique combination of bactericidal and sterilization activities.
The Bangladesh therapy with TB47 may be resistant to previous treatments.
The treatment course of more than 9 months for multi-drug tuberculosis is shortened to less than 5 months, which is close to the current 6-month treatment course required for the treatment of common tuberculosis with four first-line drugs
.

However, this therapy uses injection drugs, and pure oral treatment is the current trend in the development of anti-tuberculosis drugs and new therapies.
On the one hand, oral administration can reduce the pain of injections for patients, and on the other hand, it can also facilitate patients to reduce going out for medical treatment and increase patients.
Compliance
.
In addition, the previous therapies contained pyrazinamide and quinolone drugs.

The study shows that the combination of TB47 and the patent expired oral medicine has a good cure effect for MDR tuberculosis.
TB47+clofazimine+linezolid is used as a fixed combination, and the use of linezolid does not exceed 3 months
.
This combination + pyrazinamide four-drug combination can achieve zero recurrence within ≤ 4 months, that is, the combination may cure MDR tuberculosis in ≤ 4 months, even faster than the four first-line drugs for ordinary tuberculosis

The treatment time of pyrazinamide-free TB47+clofazimine+linezolid triple-drug combination to achieve a complete cure takes 5-6 months, which is basically close to the course of treatment of common tuberculosis with four first-line drugs
.
In addition, it is extremely difficult to clinically detect the drug sensitivity of tuberculosis to pyrazinamide and the drug resistance rate of MDR tuberculosis to pyrazinamide is very high.

Zhang Tianyu pointed out that in recent years, China's new anti-tuberculosis drugs have made good progress
.
For example, the improved clofazimine (pirfazine, which reduces skin discoloration caused by clofazimine) has completed phase I clinical studies, and linezolid derivatives that further reduce side effects have been approved for clinical use

Related paper information: https://doi.